AOD 9604 5mg

AOD-9604 — GH Fragment 176-191 by Dragon Pharma

AOD-9604 is Dragon Pharma's formulation of the synthetic GH peptide fragment at 5mg per vial — specifically the C-terminal amino acids 176-191 of the human growth hormone molecule, the region responsible for GH's fat-metabolising properties. Unlike full Somatropin (HGH), AOD-9604 does not elevate IGF-1, does not increase insulin resistance, and does not produce the anabolic effects of full GH — it isolates only the lipolytic fragment for targeted fat metabolism.

Also searched as: AOD 9604, GH fragment 176-191, Anti-Obesity Drug 9604, AOD-9604 Dragon Pharma.

What AOD-9604 Means — Name and Origin

The name and origin of AOD-9604 are rarely explained in competitor content:

• AOD stands for Anti-Obesity Drug — reflecting the original research purpose; Monash University in Melbourne, Australia developed AOD-9604 in the 1990s specifically to isolate the fat-metabolising region of growth hormone without its anabolic or diabetogenic effects
• 9604 is the compound reference number from the original Monash University/Metabolic Pharmaceuticals development programme
• The compound reached Phase IIb/III clinical trials for obesity treatment in the early 2000s before development was deprioritised commercially — generating human clinical data in obese subjects that validates its fat loss mechanism
• AOD-9604 received GRAS (Generally Recognised As Safe) designation from the FDA in 2014 for use as a food ingredient — making it one of the few peptides in this space with formal safety recognition from a regulatory body

Why AOD-9604 Does Not Raise IGF-1 — The Fragment Mechanism

This is the most important and most poorly explained aspect of AOD-9604 and the primary reason it differs from full HGH:

• Full growth hormone (191 amino acids) has multiple regions with different biological functions. The N-terminal region (amino acids 1-43 approximately) is responsible for GH's anabolic effects including IGF-1 stimulation, cell growth and insulin resistance
• AOD-9604 is only the C-terminal fragment (amino acids 176-191) — this region mimics the lipolytic activity of GH by stimulating the beta-3 adrenergic receptor in adipose tissue and inhibiting lipogenesis, without engaging the receptor domains required for IGF-1 stimulation
• Consequence: AOD-9604 provides GH-like fat metabolism effects without the IGF-1 elevation that drives cell proliferation, without increased insulin resistance, and without the muscle-building effects of full HGH
• This makes AOD-9604 specifically useful for users who want fat loss support without altering IGF-1 levels — particularly relevant alongside AAS cycles where IGF-1 may already be elevated, or for users who specifically do not want the anabolic effects of full HGH

AOD-9604 vs Full HGH (Somatropin) — The Critical Comparison

Effects and Benefits

• Targeted lipolysis via beta-3 adrenergic receptor stimulation in adipose tissue
• Inhibition of lipogenesis — reduces formation of new fat deposits
• No IGF-1 elevation — does not drive cell proliferation or anabolic effects
• No insulin resistance — can be used safely alongside carbohydrate-containing nutrition without the glucose dysregulation concern of full HGH at higher doses
• No suppression of natural testosterone, thyroid or HPG axis
• Some preliminary research suggests cartilage repair potential — though this is less established than BPC-157 or TB-500 for this purpose

Dosage and Administration